NCT04493853: An ongoing trial by AstraZeneca
This trial is completed, but has been granted a delay in reporting its results.
It must report results 1 year, 9 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT04493853 |
|---|---|
| Title | A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib+Abiraterone Versus Placebo+Abiraterone as Treatment for Patients With DeNovo Metastatic Hormone-Sensitive Prostate Cancer Characterised by PTEN Deficiency. |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | July 13, 2020 |
| Completion date | Oct. 7, 2024 |
| Required reporting date | Oct. 7, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |